News | October 11, 2021
Sai Life Sciences presents its midterm report
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries
The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service
A total of 8308 stores are open across India and medicines are priced at affordable rates
The initiative will create an integrated network of Critical Care Units (CCUs) across the Apollo Hospitals network but also in partnership with non-Apollo units in India and overseas
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
More than 90,000 patients utilise the services daily
The first clinical trial is expected to commence in early 2022 both in Europe and the US
Subscribe To Our Newsletter & Stay Updated
